Insulet (PODD) stock is drawing attention after the company announced a global partnership with Calm to offer free mindfulness and sleep resources tailored to people living with diabetes and their caregivers.

The Calm partnership lands at a time when Insulet's recent 30 day share price return of 4.27% contrasts with a year to date decline of 41.68% and a 1 year total shareholder return decline of 43.55%. This suggests short term momentum has picked up while longer term performance remains weak.

If this focus on diabetes care has your attention, it could be a good moment to look at other healthcare related technology by checking out our 40 healthcare AI stocks

For Insulet, a 4.27% gain over 30 days, compared with a much weaker 1-year record, raises a simple issue: is the market reassessing the business, or just adjusting sentiment ahead of what the current valuation implies?

Most Popular Narrative: 31.9% Undervalued

The most followed narrative currently places Insulet’s fair value at $242.43 per share, well above the last close of $165.00. It frames the Calm partnership against a wider growth and margin story.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and integration with the latest glucose sensors, is described as positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting strong top-line revenue growth.

Accelerating penetration of the large, underpenetrated type 2 diabetes segment, supported by positive pivotal trial data (SECURE-T2D) and improved access and affordability (broad pharmacy distribution, low co-pays), is presented as a growth engine that increases Insulet's addressable market and supports ongoing customer base growth, contributing to recurring revenue streams.

Want to see what sits behind that fair value gap for Insulet? The narrative focuses on faster revenue expansion, rising margins, and an earnings profile built around Omnipod growth and type 2 adoption. The exact path, and the profit multiple it assumes, are where the story becomes more detailed.

Result: Fair Value of $242.43 (UNDERVALUED)

However, the Insulet story also depends on execution, with heavy investment and a single core Omnipod platform leaving the business exposed if adoption or pricing disappoints.

Another View on Insulet’s Valuation

While the narrative flags Insulet as 31.9% undervalued based on fair value estimates around $242 per share, the current P/E of 37.3x tells a tougher story. It sits above the US Medical Equipment industry at 26.7x and above a fair ratio of 32.1x, which points to valuation risk if expectations ease instead of catching up.

For investors comparing these signals, the question is simple: is Insulet priced for a story that is already in the share price or for one that still needs to be earned, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around Insulet’s recent share price and valuation, it makes sense to review the underlying data yourself and decide what really matters. If you want a quick summary of both the main concerns and the key positives investors are watching, check out the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Insulet?

If Insulet has sharpened your focus on where capital works hardest, do not stop here. The right watchlist can be the difference between reacting and being ready.

• Shift your attention toward potential mispriced opportunities by checking out the 50 high quality undervalued stocks that currently match strict quality and valuation filters.
• Strengthen your defense by reviewing the 84 resilient stocks with low risk scores that pair resilient business profiles with lower overall risk scores.
• Get ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems that combine robust fundamentals with limited mainstream attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.